RegeneRx Biopharmaceuticals Inc (RGRX)

[SPM555]

RegeneRx's TB4 Shown to Significantly Limit Brain Damage After Stroke by Upregulating microRNA-200a PR Newswire   "Press Releases US - English"

ROCKVILLE, Md. , Oct. 20, 2015 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX)("RegeneRx" or the "Company"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced a new scientific publication in the most recent issue of the Journal of Neurochemistry describing how Thymosin beta 4 (TB4) reduces neurological injury following a stroke by up-regulating the expression of microRNA-200a (miR-200a).

The authors found that miR-200a, a very short and specific piece of RNA, is increased in the presence of TB4 in an in vitro stroke model, as well as when TB4 is administered systemically ina similarmodel. This increased miR-200a results in the down-regulation of a number of proteins that can negatively affect the repair of damaged tissue, in this case central nervous system tissue around the area damaged by the stroke.